^
Association details:
| Biomarker: | MET-ATXN7L1 fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MET gene fusions in non-small cell lung cancer (NSCLC) in the Chinese population: A multicenter study.
Published date:
05/16/2018
Excerpt:
The patient was a 56-year-old never smoking female, who was diagnosed with lung adenocarcinoma...Biopsies were obtained from metastatic sites, MET-ATXN7L1 fusion, was found by NGS...The patient was considered to have a partial response (PR) to crizotinib, and she was alive up to now.
